Mutational analysis from circulating tumor cells using next-generation sequencing (ACTC 2014)


Tumor mutational analysis provides insight into patient drug response, prognosis, and tumor biology. A key limitation to this process is the availability of tumor tissue that adequately represents the current disease status. This study presents a Next Generation Sequencing (NGS) works utilizing enriched circulating tumor cells (CTCs) as an input. The CTC enrichment is performed using the IsoFlux System that accommodates multiple capture antibody cocktails and has been shown to be eective across multiple indications.